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Osteoarthritis (OA) is a degenerative joint disease that is characterized by increasing loss of cartilage, remodeling of the
periarticular bone, and inﬂammation of the synovial membrane. Besides the common OA therapy with nonsteroidal anti-
inﬂammatory drugs (NSAIDs), the treatment with chondroprotectives, such as glucosamine sulfate, chondroitin sulfate,
hyaluronic acid, collagen hydrolysate, or nutrients, such as antioxidants and omega-3 fatty acids is a promising therapeutic
approach. Numerous clinical studies have demonstrated that the targeted administration of selected micronutrients leads to
am o r ee ﬀective reduction of OA symptoms, with less adverse events. Their chondroprotective action can be explained by a
dual mechanism: (1) as basic components of cartilage and synovial ﬂuid, they stimulate the anabolic process of the cartilage
metabolism; (2) their anti-inﬂammatory action can delay many inﬂammation-induced catabolic processes in the cartilage. These
two mechanisms are able to slow the progression of cartilage destruction and may help to regenerate the joint structure, leading to
reduced pain and increased mobility of the aﬀected joint.
1.Introduction
Osteoarthritis (OA), the most common type of arthritis, is
characterized by gradual wear and loss of cartilage in the
joints resulting in friction between the bones, which leads to
pain and swelling. It was long thought that only the cartilage
is aﬀected. However, it is now known that the underlying
bone, as well as the synovium, also undergoes changes [1–
3]. The periarticular bone reacts with osteophyte formation
which causes additional restriction in joint movement. It
can occur in any joint, but predominates in weight-bearing
joints, such as the knee and hip. In Germany, the prevalence
of diagnosed osteoarthritis (all age groups combined) in at
least one joint is 27%, and more than 50% of the population
over 60 suﬀer from OA in at least one joint [4]. In the
United States of America, OA is responsible for total joint
replacement in half a million Americans each year [5],
indicating that OA is not only a burden to the patients, but
also a ﬁnancial burden on society.
Common OA therapy focuses mainly on the treatment
of symptoms, such as pain reduction, but does not treat
the cause. However, the main goal of OA therapy should be
to delay cartilage degeneration and even help to regenerate
the cartilage structure. One approach in this direction is the
treatment with chondroprotectives, diﬀerentiated in symp-
tomatic slow-acting drugs in OA (SYSADOA) or structure-
modifying OA drugs (SMOAD).
This paper will focus on the ability of such chon-
droprotectives to retard the degenerative process of cartilage
destruction and will discuss the evidence of symptomatic
and structure-modifying eﬀects of this nutritional approach.
Furthermore, the role of inﬂammation and especially obesity
in the process of osteoarthritis and how this process could be
addressed will be discussed.
2. Common Risk Factors for
the Development of Osteoarthritis
There are still questions concerning the causal factors of
OA. The nature of the initiating event is often unknown,
although many processes involved in the progression of2 International Journal of Rheumatology
OA are known. Due to disruption of the cartilage collagen
matrix, the water content of the cartilage increases. Together
withtheprogressivelossofproteoglycans,theelasticityofthe
cartilage diminishes. This is followed by a progressive loss
of cartilage and the formation of osteophytes and calcium
deposits. Osteophytes further limit ﬂexibility of the joint. OA
progression is associated with synovial inﬂammation, joint
swelling, stiﬀness and pain, leading to progressive functional
impairment [5, 6].
There are several known risk factors. One of the primary
risk factor for OA is age [3, 7]. During aging, the articular
cartilage softens. The ability to remodel and repair the
cartilage extracellular matrix (ECM) decreases with age [8].
Furthermore, changes are due to the structural organization
of the ECM [9, 10]. During aging, cross-linking of collagen
ﬁbers is enhanced which results in increased cartilage
stiﬀness [11]. Aging also leads to reduced muscle mass and
strength, which in turn reduces joint stability and leads to
misalignment.Thiscancauseabnormalmechanicalstresson
the joint and thus cartilage degeneration [12].
Anothercommonlyacceptedriskfactorisoverweightand
obesity. A recent meta-analysis addressed the incidence of
comorbidity related to overweight and obesity. It was able
to show that overweight and obesity lead to a signiﬁcantly
higher OA risk [13]. The mechanisms by which obesity
contribute to OA development are described below.
A number of studies demonstrated that there are strong
geneticdeterminantsforOA(forreviewsee[14,15]).Aclassic
twin study in which twins were radiologically screened for
OA, showed a clear genetic inﬂuence on hand and knee OA
in women. Hence the genetic inﬂuence was calculated to
be 39–65% [16]. Several genetic abnormalities have been
identiﬁed that are responsible for the onset and progression
of OA. These gene variations result in defects or variability of
cartilageandECMcompositionandmetabolism[14,17,18].
Patients with developmental dysplasia of joints, such
as hip dysplasia, develop OA much earlier than normal
individuals. Misalignment leads to a reduced contact area
within the joint resulting in locally elevated pressure on the
cartilage [19]. This is related to the progression and onset
of OA [20, 21]. Injuries involving the joint surface, injured
ligaments, or meniscectomy, are also associated with the
development of OA. Injuries can often cause joint movement
beyond the physiological range which leads to uneven load
distribution in the joint.
Despite the diﬀerence in the primary causes of OA, they
all lead to similar clinical symptoms, cartilage destruction,
bone remodeling, osteophyte formation, inﬂammation of
the synovial membrane, pain, and immobility.
3. Regeneration of the Cartilage Structure
3.1. Basic Structure and Turnover of Normal Joint Cartilage.
To understand the structure-modifying eﬀect of diﬀerent
nutrients and how they can support the process of cartilage
regeneration, it is important to know the composition of
cartilage and the metabolic mechanisms involved in normal
turnover.
HA
G1G2
LP KS
CS 2
CS 1
G3
Figure 1: Schematic representation of the aggrecan structure (HA:
hyaluronic acid, CS 1, CS 2: chondroitin sulfate domains 1 and 2;
KS:keratansulfate;G1,G2,G3:globulardomains;LP:linkprotein).
Cartilage is classiﬁed into three diﬀerent types, based
on the collagen type used and the relative amount of the
main components, that is, elastic cartilage, hyaline cartilage,
and ﬁbrocartilage. Unlike other tissue it is not innervated
and does not contain blood vessels or lymphatic structures.
There are only a small number of chondrocytes within the
cartilage and they only account for 1–5% of the cartilage
volume. The chondrocytes are responsible for maintaining
the composition and organization of the matrix. They
produce this extracellular matrix composed of collagen and
elastin ﬁbers, as well as proteoglycans.
Hyaline cartilage, found in joints, is characterized by
its high elasticity and pressure resistance. In contrast to
bone and muscle, it does not increase its tissue mass
postnatally due to mechanical stimulation. The morphology
of cartilage seems to be strongly related to genetic factors
[22]. It is composed of four diﬀerent zones: the superﬁcial
tangential zone, the middle or transitional zone, the deep
or radial zone, and the calciﬁed cartilage zone [23, 24]. The
collagen network of the joint cartilage consists mainly of
type II collagen ﬁbrils. Collagen ﬁbers are important for the
response to tensile forces within the joint.
Proteoglycans are intertwined with the collagen network.
Due to the net negative charge of the proteoglycans, a
large amount of water is enclosed in the cartilage. The
water content is important for the resilience and elasticity
of the tissue, as well as for lubrication of the joint sys-
tem. The proteoglycans of the articular cartilage are large
supramolecularcomplexes,composedofacentralhyaluronic
acid (HA) ﬁlament, to which aggrecan molecules composed
of chondroitin sulfate and keratan sulfate are attached by
a link protein in a brush-like conﬁguration (see Figure 1).
The amino sugar glucosamine is a necessary component for
the synthesis of many of these proteoglycans, which include
hyaluronic acid, heparan sulfate, and keratan sulfate. The
production of glucosamine is one of the rate-limiting steps
in proteoglycan production.
The ability of the articular cartilage to regenerate or
adapt to mechanical changes is very limited. It has beenInternational Journal of Rheumatology 3
postulated that this inability to adapt to mechanical changes
is related to its inability to repair after mechanical or other
damage[25].Onereasonistheavascularnatureofthistissue,
which makes it diﬃcult to move progenitor cells to lesion
sites. In in vivo models of rabbits and goats, it has been
shown that lesions smaller than 3mm in diameter can heal
(chondral or subchondral zone) while defects larger than
6mm in diameter rarely if ever heal and lead to progressive
degeneration (for review see [26]).
Due to the lack of blood vessels, the chondrocytes
within the cartilage receive nutrients only by diﬀusion from
the surrounding tissue. Therefore, a large amount of basic
components should be available in that tissue.
The viscous synovial ﬂuid is composed of hyaluronic acid
(hyaluronan), lubricin (a large, water-soluble glycoprotein),
glucose,andwater.Hyaluronanissynthesizedbythesynovial
membrane and released into the joint cavity.
3.2. Chondroprotectives. As shown above, glucosamine, hy-
aluronic acid, and chondroitin sulfate are important basic
natural components of cartilage and synovial ﬂuid. They are
naturally formed by the body, but can also be provided in the
diet.
Supplementation of such basic components may be ben-
eﬁcial, especially when there is a disturbed balance between
catabolic and anabolic processes, such as in osteoarthritis.
During OA progression, the chondrocytes are no longer able
to fully compensate for the loss of collagen type II ﬁbers and
proteoglycans, even at increased synthesis rates [24].
It has been shown in many in vitro and in vivo trials and
in numerous clinical studies that these SMOAD can modify,
stabilize, retard, or even reverse the pathology of OA.
3.2.1. Glucosamine Salts. Glucosamine or 2-amino-2-deoxy-
D-glucose (C6H13NO5) is an amino monosaccharide. It
is synthesized from glucose in almost every human tissue
and is most abundant in connective tissue and cartilage.
Glucosamine can be extracted from chitin, found primarily
in the exoskeleton of crustaceans (crabs, prawns, and
lobsters), as well as in the cell membranes of mushrooms.
It is an important precursor of the glycoprotein and gly-
cosaminoglycan (GAG) synthesis. Within cartilage, it is most
important for the formation of hyaluronic acid, chondroitin
sulfate as well as keratan sulfate, which are—aside from
the collagen ﬁbers—the most important components of the
extracellularmatrixofthearticularcartilageandthesynovial
ﬂuid (for review see [6, 44, 45]). Glucosamine production
is the rate-limiting step in GAG synthesis, and glucosamine
supplementation may overcome this bottleneck.
Due to its basic role in cartilage and synovial ﬂuid syn-
thesis, glucosamine—administered as glucosamine sulfate
(GlcN·S) or hydrochloride (GlcN·HCl)—has been tested
in numerous clinical OA trials and the eﬀects have been
summarized in reviews and meta-analyses [6, 33, 34, 37, 38,
44–50].
A recent comprehensive review published in 2010 [51],
summarized, on the basis of peer-reviewed publications, the
currently available chemical and pharmacokinetic data of
GlcN salts, and their role in the treatment of clinical OA.
An important aspect of GlcN is the structure of various
oral GlcN compounds: regardless of the nature of the salt,
GlcN·HCl or GlcN·S, the organic component glucosamine
is structurally identical. GlcN·HCl dissociates completely in
the stomach to GlcN and HCl, and GlcN·S dissociates to
GlcN, HCl, sodium sulfate, and sulfuric acid. Investigators
have claimed in favor of the GlcN sulfate salt that the sulfate
anion would stimulate the chondroitin sulfate synthesis,
however,toachievethisserumconcentrationsof50timesthe
serum sulfate concentration would be necessary [51].
In horse studies (see e.g., [52]) Cmax was about 10μM
at 2h, and here also, the sulfate and chloride salts of GlcN
were essentially identical. In human volunteers Cmax was
determined to be between 1 and 4 hours after ingestion of a
dose of 20mg GlcN·S per kg body weight (for a typical adult
with a body weight of 75kg, this corresponds to a daily dose
of 1500mg). In four pharmacokinetic studies in humans,
maximum serum levels were between 9 and 11μm, and in
one group of OA patients, mean Cmax was 7μM. Laverty
et al. [52] were the ﬁrst to demonstrate that free GlcN can
be detected in synovial ﬂuid after administration (cited in
[53]). They found that the synovial ﬂuid concentrations of
GlcN remained elevated in most animals even at 12h after
administration. This is in contrast to the nearly complete
clearance of GlcN in serum 6 hours after dosing.
In Vitro Studies. In vitro studies on isolated chondrocytes,
or cartilage explants from healthy or OA patients, provide
much evidence for the proposed mechanisms regarding how
glucosamine supports joint health. It has been shown that
glucosamine enhances the production of cartilage matrix
components in chondrocyte culture, such as aggrecan and
collagen type II [54, 55]. Glucosamine increases hyaluronic
acid production in synovium explants [56]. Further exper-
iments have shown that glucosamine prevents collagen
degeneration in chondrocytes by inhibiting lipoxidation
reactions and protein oxidation [57]. MMPs (matrix metal-
loproteinases) and aggrecanases are the predominant cleav-
age enzymes in the cartilage. These enzymes are responsible
for cleavage preferentially in the interglobular domain of
the aggrecan molecule, which leads to loss of aggrecan
function [24]. Glucosamine is able to inhibit the MMP
synthesis, and further proteoglycan degeneration is therefore
prevented [58, 59]. Glucosamine also inhibits aggrecanase by
suppression of glycosylphosphatidylinositol-linked proteins
[60]. Inﬂammatory processes, which are also responsible for
degeneration of the cartilage, are inhibited by glucosamine.
These mechanisms will be explained in Section 4.
Selected Clinical Trials. The summarized data of major
clinical trials (RCTs) between 2001 and 2007 with form of
glucosamine used, active reference agents, patient character-
istics, outcome measure, and results are listed in Table 1.
The positive eﬀects of glucosamine on the progression of
kneeOAwasnotshowninpatientssuﬀeringfromhipOA.In
a recent clinical trial, GlcN·S (1500mg/day) was not able to
show superiority over placebo [61], even when a subgroup4 International Journal of Rheumatology
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analysis of the available data was made [62]. The reason
why GlcN·Si se ﬀective for knee OA, but not for hip OA, is
unclear.
Furthermore, it is not understood why many trials stated
that there was a signiﬁcant superiority of GlcN·So v e r
placebo or NSAIDs (e.g., Qiu et al. [63]), whereas others did
not. Other trials failed to achieve signiﬁcance due to a high
placebo eﬀect. The heterogeneity of the subjects was also a
possible reason, as well as bias due to industry funding. The
opinions on this diﬀer and have recently caused much debate
[35, 64, 65].
Selected Reviews and Meta-Analyses. The quality of evidence
was recently evaluated by comparing data from clinical
studies, meta-analyses, and reviews (published between 1950
and 2007) on the eﬀect of SYSADOA, including glucosamine
sulfate [33]. Using a specialized rating method (GRADE), 5
meta-analyses and one comprehensive review were identiﬁed
whichwereincludedintheevaluationofglucosaminesulfate.
Based on this data, it was concluded that glucosamine
sulfate,amongothers,has“demonstratedpainreductionand
physical function improvement with very low toxicity, with
moderate to high quality evidence” [33]. The results of the
Cochrane review by Towheed et al. [34] were included in
their evaluation.
The summarized data of selected systematic reviews/
meta-analyses, published between 2005 and 2008 with their
conclusions are listed in Table 2.
In most trials, dosages of 1500mg/day were used; the
dose was as safe as placebo and was tolerated better than
NSAIDs.
From the clinical trials, it can be concluded that long-
term treatment with glucosamine:
(i) reduces pain,
(ii) improves function/mobility of the joint,
(iii) reduces OA progression,
(iv) reduces risk of total joint replacement.
The European League Against Rheumatism (EULAR)
came to similar conclusions and rated GlcN·S in their
guidelines for knee OA with the highest level of evidence, 1A,
and recommended its use with an A [66].
The results of all these studies demonstrate that glu-
cosamine has many favorable eﬀects on cartilage. First, it
has shown an anabolic stimulating eﬀect on cartilage syn-
thesis. Furthermore, it inhibits by means of several anti-
inﬂammatory and antioxidant mechanisms, the catabolic
cartilage degenerating reactions observed in OA (see
Section 4).ThiscandelaycartilagedegenerationinOAwhich
leads to a reduction in pain and swelling as well as to
increased mobility of the aﬀected joint.
3.2.2. Chondroitin Sulfate. Chondroitin sulfate (CS) is one
of the natural glycosaminglycans (GAG) composed of the
alternating sugars D-glucuronic acid (GlcA) and N-acetyl-
D-galactosamine (GalNAc). It is an important component of
theextracellularmatrix(ECM).CSisthemostfrequentGAG
in the aggrecan molecule of the cartilage. Due to the negative
charge of CS, it is responsible for the water retention of the
cartilage,whichisimportantforpressureresistance.Itcanbe
extracted from the cartilaginous tissue of cows, pigs, birds,
and ﬁsh (sharks) and is ingested in the diet.
In the European League Against Rheumatism (EULAR)
recommendation concerning knee OA, they gave CS both
the highest evidence grade and the highest recommendation
strength, 1A and A, respectively [66]. CS is one of the
SYSADOA. The ﬁrst eﬀects of SYSADOA treatments, other
than analgesics and NSAIDs, become noticeable after 2
to 3 weeks of regular intake and has a prolonged eﬀect
that remains for up to several months. CS inﬂuences the
symptoms of OA such as pain and inﬂammation, but also
acts as a structure-modifying drug in OA (SMOAD). It may
retard OA progression and could modify the course of OA
(for review see [39]; details from this systematic review on
the clinical use of oral CS in OA is provided in Table 3).
The ability of CS to slow down the development of OA
has been demonstrated in several clinical trials [43, 67, 68].
These results were conﬁrmed in a recent long-term study
(see also Table 3 for trial data; [42]). With this study, the
authors were able to conﬁrm the results of a study performed
previously (see Table 3;[ 43]).
T h ep o s i t i v ei m p a c to fC So nO Aw a sa l s oc o n ﬁ r m e d
by meta-analyses, which all showed a signiﬁcant favorable
eﬀect of CS over placebo [33, 40, 41]. Another compre-
hensive review of CS was written by the Natural Standard
Monograph team. These authors listed 39 clinical studies or
meta-analyses in which CS was used to treat OA. Most of
these studies came to the conclusion that CS has a signiﬁcant
positive eﬀect on OA patients [69].
One of the studies without a signiﬁcant eﬀect was the
GAIT study [28] (see Table 1 for further details). In that
study, intake of CS resulted in only a 5.3% higher responder
rate than placebo, which was not statistically signiﬁcant.
However, treatment with CS led to a statistically signiﬁcant
improvement in knee joint swelling [28]. The statistical
nonsuperiority of CS in pain reduction can probably be
explained by the unexpectedly high placebo eﬀect in this
study (61% responder). All of the studies and meta-analyses
[37, 40, 41, 70] gave CS an excellent safety proﬁle, therefore
there are no safety concerns for long-term use [71].
Similar to the GAIT study, many clinical studies tested
chondroitinsulfatetogetherwithglucosamine[6,47,72–74].
The results suggest that both components may enhance each
other’s eﬃcacy. This synergistic eﬀect was also proposed by
various in vivo and in vitro studies [55, 75–78].
CS increases the hyaluronan production by human
synovial cells, which has a beneﬁcial eﬀect on maintaining
viscosity in the synovial ﬂuid [79]. It has been shown
that CS stimulates the chondrocyte metabolism, leading
to the synthesis of collagen and proteoglycan, the basic
components of new cartilage. Furthermore, CS inhibits
the enzymes leukocyte elastase and hyaluronidase, which
are found in high concentration in the synovial ﬂuid of
patients with rheumatic diseases. CS also increases the
production of hyaluronic acid by synovial cells, which subse-
quently improves the viscosity and the synovial ﬂuid levels.6 International Journal of Rheumatology
Table 2: Characteristics and results of selected reviews/meta-analyses-glucosamine.
Author(s), year Analyzed publications Trial details Conclusions
Bruyere et al. 2008 [33]
(i) Towheed et al., Cochrane
Review 2005 [34]
20RCTs: GlcN·S superior to Plac.
with a 28% improvement in pain
and a 21% improvement in
function (Lequ. index).
Signiﬁcantly superior to placebo in
terms of its ability to reduce levels of
pain.
(ii) Vlad et al. 2007 [35]
15RCTs Summary eﬀect sizes
ranged: 0.05 to 0.16 in trials
without industry involvement, but
0.47 to 0.55 in trials with industry
involvement.
Heterogeneity among trials of
glucosamine is larger than would be
expected by chance. Glucosamine
hydrochloride is not eﬀective.
(iii) Reginster 2007 [36]
(update following Richy et al.
2007, [37])
3 pivotal RCTs: WOMAC pain and
function subscores: signiﬁcant
beneﬁcial eﬀect of GlcN·Sv e r s u s
Plac.
The eﬀect size was consistent across
the parameters, and it was approx.
0.30 or slightly higher. This eﬀect is
small to medium, but it is clinically
valid (>0.20), and especially, it is of the
same magnitude as that commonly
encountered with other OA
treatments, including NSAIDs.
Poolsup et al. 2005 [38]
14 RCTs: GlcN·S: Risk of disease
progression was reduced by 54%
(P = 0.0011).
Pooled eﬀect sizes for pain
reduction and improvement in
physical function were 0.41
(P<0.0001) and 0.46 (P<0.0001),
respectively.
GlcN·Sm a yb ee ﬀective and safe in
delaying the progression and
improving the symptoms of knee OA.
In general, CS inhibits cartilage destruction processes and
stimulates the anabolic processes involved in new cartilage
formation (for review see [6, 69]). In addition, CS, when
added to chondrocyte cultures, produces a dose-dependent
increase in cell proliferation.
Several mechanisms are discussed which lead to the
positive impact of CS on OA patients. Pharmacokinetic
studies were able to show that orally ingested chondroitin
sulfate is absorbed as a high molecular mass polysaccharide
and can be detected in plasma, together with derivatives,
resulting from partial depolymerization and/or desulfation
[80]. A pharmacokinetic study (1990) in rats and dogs
[81] tested the distribution of tritiated CS orally and
intramuscularly. More than 70% of the orally administered
radioactivity was absorbed. Independently of the route of
administration, radioactivity was mainly excreted through
the urine. Plasma levels showed a rapid increase after oral
administration, followed by a large plateau with a maximum
after 14 or 28 hours in rats and dogs, respectively.
IntheyearsafterthepublicationoftheGAITstudy,using
a combination of GlcN·HCl and CS, new pharmacokinetic
data in humans, for both chondroprotectives became avail-
able. Jackson et al. [82] tried to assess the pharmacokinetic
behavior of oral GlcN and CSeither separately or combined.
First they found that the basal levels of GlcN in plasma were
at any time below the detection limit, while with CS plasma
levels were approximately. 20μg/mL and did not show any
circadian variation. In a second trial phase, they examined
the pharmacokinetics of 1500mg of GlcN·HCl, 1200mg CS,
or a combination of both substances. In a third phase, they
selected a group of patients with symptomatic knee OA (as
part of GAIT) who had already received 1500mg GlcN·HCl,
1200mg CS, or a combination of both for more than 3
months every day. The main ﬁnding was that none of the
experimentalproceduresledtoalterationsintheendogenous
plasma CS concentration. The basal GlcN levels in plasma
which had not been detectable before increased, but with
combinedadministrationtogetherwithCSweresigniﬁcantly
reduced.
The authors concluded that the clinical improvement of
OA symptoms which was obvious in the numerous clinical
trials (also for a subgroup of the GAIT patient population,
[28]) is not caused by a synergistic eﬀect of both agents
during intestinal absorption, but that there may be indirect
eﬀects of these two agents on joint health. They hypothesize
that the favorable clinical eﬀects of both compounds may
result from “changes in cellular activities in the gut lining or
intheliver,whereconcentrationsofingestedCS,oritsbreak-
downproducts,couldbesubstantiallyelevatedfollowingoral
ingestion” [82].
In summary, all the information from these in vitro and
invivostudies,theclinicaltrials,aswellasmeta-analyseslead
to the conclusion that there is suﬃcient data to support the
use of oral CS in OA. The ﬁndings show that CS reduces
pain, improves function/mobility of the joint, and reduces
the progression of OA by its structure-modifying eﬀects.
3.2.3. Other Compounds. In addition to the combination
GlcN·S + CS, other related substances, for example,International Journal of Rheumatology 7
Table 3: Characteristics and results of selected meta-analyses and RCTs-chondroitin sulfate.
(a)
Author(s), year Analyzed publications Trial details Conclusions
Uebelhart 2008 [39] Meta-analysis
3RCTs with CS in knee OA:
462pts., 2 ×3mo. 800mg for 1yr;
800mg daily and continuously for
12 and 24 months.
2RCTs with CS in ﬁnger joint OA:
284pts., 3 ×400mg CS for 3yrs.
CS decreased the number of pts.
with new erosive OA ﬁnger joints.
CS inﬂuences the symptoms of OA such
as pain and inﬂammation, but also acts as
a structure-modifying drug in OA
(SMOAD).
CS may retard OA progression and could
modify the course of OA.
Lee et al. 2010 [40] Meta-analysis
2RCTs with GlcN·S + 4RCTs with
CS (800mg daily) in OA:1502pts.
CS: Small, but signiﬁcant protective
eﬀect on minimum joint space
narrowing after 2 years (P<0.001).
CS may delay radiological progression of
OA of the knee after daily administration
for over 2 years.
Hochberg et al. 2008
[41] Meta-analysis
3RCTs with CS in knee OA: Small
signiﬁcant eﬀect on the reduction in
rate of decline in minimum joint
space width of 0.07mm/year.
The eﬀect size is 0.26 (P<0.0001).
CS is eﬀective for reducing the rate of
decline in minimum joint space width in
OA of the knee; CS may have a role as a
structure-modifying agent in the
management of patients with knee OA.
(b)
Author(s), year CS/Dose Duration Pts. (n) Outcome measure Results and conclusion
Kahan et al. 2009 (STOPP:
Study on Osteoarthritis
Progression Prevention)
[42]
CS/800mg 2yrs 622 (knee OA) CS:
309
X-ray images,
tibiofemoral joint:
joint space narrowing
Progression of joint space
narrowing was signiﬁcantly reduced
versus plac.
(28% CS pts. versus 41% Plac. pts.
showed progressive joint space
narrowing, P<0.0005)
Combined structure- and
symptom-modifying eﬀects of CS
s u g g e s tt h a ti tc o u l db ea
disease-modifying agent in patients
with knee OA.
Michel et al. 2005 [43] CS/800mg 2yrs 300 (knee OA) CS:
150
X-ray images,
tibiofemoral joint:
joint space narrowing
CS: no signiﬁcant joint space loss,
P = 0.04 versus Plac.
Plac.: signiﬁcant joint space
narrowing (P = 0.001 versus
baseline)
CS: no signiﬁcant symptomatic
eﬀect, but halts structural changes
in OA for over 2 yrs.
hyaluronic acid (HA, hyaluronan) and collagen hydrolysate,
have been used in OA patients.
Regarding therapeutical use of HA, the backbone of
a proteoglycan aggregate within the ECM, not all clinical
trials reported the same positive result. It seems that higher-
molecular-weighthyaluronicacidmaybemoreeﬀectivethan
lower molecular-weight HA. Intra-articular treatment with
HA has been accepted and is widely used as OA therapy.
However, there is a controversy over the eﬃcacy of orally
administered HA.
Based on basic pharmacokinetic research it has been
found that orally administered high-molecular-weight HA
also reached the joint [83], which provides a rationale for
the oral supplementation of HA. Authors of a clinical pilot
study [84] concluded that HA enhances several aspects of
quality of life in adults with knee OA. A larger sample size
would be necessary to conﬁrm this result.
In a recent review in which the SYSADOA treatment was
analyzed using the GRADE system [33] ,e x p e r t sc a m et ot h e
conclusion that—in addition to chondroitin sulfate or glu-
cosamine sulfate—also hyaluronic acid has “demonstrated
painreductionandphysicalfunctionimprovementwithvery
low toxicity, with moderate to high quality evidence” [33]. In
summary, the described eﬀects justify the use of these three
cartilage components in patients suﬀering from OA.
For collagen hydrolysate, from the available in vitro
and in vivo studies as well as clinical trials [85, 86], it
may be concluded that collagen hydrolysate is absorbed by8 International Journal of Rheumatology
the gastrointestinal tract and incorporated into the joint
cartilage. It may lead to increased mobility and physical
function with a signiﬁcant pain relief.
4.Anti-InﬂammatoryandAntioxidant
Effects of Nutrients
4.1. Inﬂammation and Reactive Oxygen Species: New Metabol-
icApproachestoOsteoarthritis. W h i l eO Ai sn o ts y n o n ym o u s
with inﬂammatory arthropathy, new results indicate that
inﬂammation is not only a secondary event, it is involved
in the development of OA from the very beginning [87–89].
Many inﬂammatory mediators are expressed in the cartilage
and synovial tissue in early OA stages. The ﬁndings of Benito
[89] indicate that inﬂammatory mediators and nuclear
transcription factors involved in the inﬂammatory cascade
are signiﬁcantly higher in early-stage OA patients, when
compared to late-stage OA. Additionally, reactive oxygen
species (ROS) increase during OA [90–93]. The various
inﬂammatoryandoxidative processesinOAaresummarized
in Figure 2.
Many studies have identiﬁed overweight (BMI 25–
29.9kg/m2)a n dobesity (BMI >29.9kg/m2)[ 94–96]a sm a j o r
OA risk factors. Hart and Spector [97] showed that a
BMI increase of 2 units will increase the risk of knee OA
manifestation by 36%. This is not only due to the additional
weight and mechanical stress on the joints, as nonweight-
bearing joints—such as the hands—are signiﬁcantly more
aﬀected in patients with high BMI [89], due to metabolic
reactions. These include increased inﬂammation, induced
by leptin and other adipocytokines, and dietary lipids or
lipid peroxidation, which can lead to cartilage destruction.
Therefore, OA is not induced by biomechanical factors and
age alone, and several metabolic factors are also involved
[98–106].
Leptin is overexpressed in obese patients and is present in
the synovial ﬂuid, as well as articular chondrocytes [104].
Chondrocytes in joint cartilage also express leptin receptors
[107]. Under physiological conditions, leptin stimulates
the synthesis of insulin-like growth factor 1 (IGF-1) and
transforming growth factor beta (TGFb-1), two mediators
important for proliferation of chondrocyte and extracellular
matrixsynthesis,bybindingtotheleptinreceptor[103,104].
These two factors appear to have a positive anabolic impact
on the joint by increasing the cartilage matrix production.
Excessiveandpathologicalconcentrationsofleptin,however,
like those found in obese patients, have an opposite eﬀect
on chondrocytes, cartilage, and bone, leading to osteophyte
formation and cartilage degeneration [108]. Osteophytes in
the joints usually limit joint movement and thus provoke
pain.
In vitro experiments have elucidated several mechanisms
by which excessive amounts of adipokines lead to the
destruction of articular joints. In cartilage derived from
human OA patients, leptin enhances the synthesis of several
proinﬂammatory mediators, such as NO, PGE2,I L - 6 ,a n d
IL-8, via inducible nitric oxide synthase (iNOS) pathways.
By inhibiting the iNOS activity, NO synthesis was nearly
completely blocked. This reduction of NO reduces the
production of PGE2, IL-6, and IL-8 [109]. Furthermore,
membrane bound prostaglandin E synthase 1 (mPGES-1)
and COX-2 enzyme are overexpressed in the cartilage of
such patients. COX-2 further increases the production of
prostaglandins. This overexpression can be induced by IL-1
and TNF-alpha, factors released by adipose tissue. mPGES-1
mediates the production of PGE2 [110]. PGE2 overproduc-
tion enhances NO-induced cell death of OA chondrocytes
[111]. When IL-1 acts together with leptin, they can activate
nitric oxide synthase type II, which increases NO production
in chondrocytes [112]. Elevated NO levels lead to various
catabolic processes in the cartilage, such as the loss of
chondrocyte phenotype, thereby reducing production of
ECM, and to chondrocyte apoptosis, and ECM degradation
[113, 114].
Leptininducesthesynthesisofmatrixmetalloproteinases
(MMP), especially MMP9 and MMP13 [115–117], via IL-1
and TNF-alpha. MMPs are a large family of enzymes that
degrade diﬀerent components of collagen and proteoglycans
[118]. Both MMP9 (gelatinase) and MMP13 (collagenase)
are involved in cartilage damage [116, 117]. MMP13 is
produced by chondrocytes and cleaves collagen type II (the
main collagen type in articular cartilage) and the proteogly-
can molecule aggrecan, leading to structural damage of the
cartilage tissue [115]. These experiments clearly show that
obesity, mediated by leptin, exerts a proinﬂammatory and
catabolic eﬀect on cartilage, leading to apoptosis of chondro-
cytes and the degradation of the extracellular matrix.
Leptin is not the only adipokine associated with inﬂam-
matory actions. Resitin and visfatin, together with leptin,
increase the inﬂammatory status by means of various
mechanisms, which together with mechanical overload leads
to phenotype loss and apoptosis of chondrocytes, as well as
cartilage matrix degeneration [99, 101].
Thus, overweight and obesity play an important role
in the genesis of knee and hip joint OA not only as a
result of mechanical overload but also by the complex
combined action of genetic, metabolic, neuroendocrine, and
biomechanical factors and represent a signiﬁcant modiﬁable
risk factor [102] not least for this reason.
Inﬂammation is also induced by overloading the joints.
Various mechanoreceptors are expressed on the surface of
chondrocytes. It has been reported that mechanical com-
pression signiﬁcantly increases PGE2 release in chondrocyte
explants.ItwasshownthatmechanicalstressinducedCOX-2
expression and that mPGES-1 mRNA (PGE synthase 1)
and protein are increased in cartilage explants. mPGES-1 is
involved in PGE2 synthesis during inﬂammation. PGE2 is
most likely a key regulator of cartilage degeneration in OA
[119]. mPGES-1 and COX-2 have also been found to be
stimulated by IL-1 in chondrocytes [110].
Traumatic injury to the joints results in activation of
many genes, including inﬂammatory mediators, cartilage
degrading proteinases, and stress response factors [3].
Degeneration of the cartilage leads to ﬁbronectin fragments
(FN-f). Fibronectin and ﬁbronectin fragments are found in
the synovial ﬂuid after traumatic injuries. Investigators were
able to show that these fragments stimulate the expressionInternational Journal of Rheumatology 9
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Figure 2: Inﬂammatory and oxidative processes involved in OA; FN-f: ﬁbronectin fragment; IL-1 R: interleukin receptor; IR: integrin
receptor; LR: leptin receptor; MR: mechanoreceptor.
of inﬂammatory cytokines and chemokines, such as IL-8,
IL6, and IL-1, indicating that cartilage damage can result in
further progressive cartilage degradation. The stimulation of
the cytokines by FN-f is mediated by the NF-κBp a t h w a y
[120]. It was further shown that FN-f stimulates MMPs in
chondrocytes, which breaks down the cartilage [121, 122].
MMP13, for example, destroys type II collagen, the main
collagen component of the hyaline cartilage [123, 124].
Regardless of the source, increased concentrations
of inﬂammatory mediators activate speciﬁc aggrecanases
(ADAMTS-4/-5), which cleave the aggrecan molecule in
a speciﬁc region and thereby destroy the activity of this
important cartilage structure molecule [125].
Inﬂammation and oxidative stress are prominent mech-
anisms which lead to progression of OA. Thus, therapy must
also address this aspect.
4.2. How Can Nutrients Modulate Inﬂammation Processes
and Oxidative Stress Involved in Osteoarthritis? The complex
relationship between obesity and OA shows that overweight
certainly represents the most signiﬁcant modiﬁable risk
factor for avoiding knee or hip joint OA. Weight reduction
and weight stabilization on the basis of a balanced diet with
low energy density is crucial in manifest OA [127]. But
also the metabolic processes can be inﬂuenced by a dietary
therapy which mainly includes chondroprotectives, such as
glucosamine and chondroitin sulfate or omega-3 fatty acids.
An alternative treatment to the common NSAID therapy
for OA is the use of so-called nutraceuticals, such as glu-
cosamine, chondroitin sulfate, hyaluronic acid, hydrolyzed
collagen, and omega-3 fatty acids and various vitamins and
minerals. In addition to cartilage metabolism stimulation
and thereby cartilage regeneration, many of them possess
mechanisms which modulate the inﬂammatory events and
oxidative processes involved in OA. As they are components
of natural foods, they have far fewer adverse eﬀects in long-
term use than NSAIDs or COX-2 inhibitors, as shown in
many clinical trials (see above).
They interfere with the inﬂammatory scenario, illus-
trated above, at various points (see also Figure 2).
The glucosamine and chondroitin sulfate combination
suppresses IL-1-induced gene expression of iNOS, COX-
2, mPGEs, and NF-κB in cartilage explants. This leads
to reduced production of NO and PGE2, two mediators
responsible for the cell death of chondrocytes and inﬂam-
matory reactions [128, 129] .T h e r ea r es e v e r a lw a y sb y
which glucosamine or chondroitin sulfate reduce synthesis
of the COX-2 enzyme. Inhibition of the IL-1 beta induced
NF-κB pathway by glucosamine sulfate results in reduced
synthesis of the COX-2 enzyme [130–133]. Another manner
in which glucosamine hydrochloride inhibits COX-2 activity
is the prevention of COX-2 co-translational N-glycosylation
and the facilitation of COX-2 protein turnover [134]. CS
alone diminishes the nuclear translocation of NF-κB, which
reduces the formation of proinﬂammatory cytokines IL-
1beta and TNF-alpha and proinﬂammatory enzymes such10 International Journal of Rheumatology
as cyclooxygenase 2 (COX-2) and nitric oxide synthase-2
(NOS-2) (for review see [135]).
Theanti-inﬂammatory capability of CSwasalsotested in
arabbitatherosclerosismodel. Inthatmodel, CSreducedthe
proinﬂammatory molecules C-reactive protein and IL-6 in
serum, as well as the expression of MCP-1 and COX-2 in the
peripheralbloodmononuclearcells.ItalsoinﬂuencedNF-κB
[136] that is responsible for the induction of inﬂammatory
processes.
Additionally, inﬂammation mediators activate various
cartilage degenerating enzymes. The mRNA expression of
such enzymes (MMP-13 and aggrecanases (ADAMTS-5))
was reduced in cartilage explants incubated with GlcN·S
and CS. In the same study, the tissue inhibitor of metal-
loproteinase-3 (TIMP-3), a potent inhibitor of ADAMTS,
wasupregulated[128].Glucosaminesulfatealonewasshown
to inhibit the activation process of MMP-2 and MMP-
9 expression, via downregulation of the NF-κBp a t h w a y
[137].
Inﬂammatory mediators are responsible for reduced
biosynthesis of cartilage material. Experiments with rat
chondrocytes have shown that IL-1β inhibits the expres-
sionof the enzyme galactose-β-1,3-glucuronosyltransferaseI
(GlcAT-I), a key enzyme in the biosynthesis of cartilage GAG
chains. Dose-dependently glucosamine was able to reduce
this inhibition [132].
In addition to their anti-inﬂammatory action, glu-
cosamine and chondroitin sulfate exhibit an antioxidant
action which leads to a signiﬁcant reduction in iNOS
expression and activity [138, 139]. This is one explanation
why glucosamine and chondroitin reduce the otherwise
NO-induced cell death of chondrocytes. In comparison
to glucosamine and CS, hyaluronic acid exerted a very
minor anti-inﬂammatory and antiapoptotic eﬀect, while it
signiﬁcantly reduced NO levels [139].
Vitamins and Minerals. Many vitamins are known for their
antioxidant capacity. Under physiological conditions, the
reactive oxygen species (ROS), produced by the body are
neutralized by the body’s antioxidant defense system, such
as peroxidase, superoxide dismutase, or catalase. Under
disease conditions, however, the increased amount of ROS
can no longer be managed by the natural defense system.
Arthropathiessuchasosteoarthritisandrheumatoidarthritis
are characterized by the increased formation of free radicals
[98, 102, 140]. ROS, which are extensively expressed during
OA [92, 93, 141, 142], are involved in matrix and cartilage
degeneration, inhibition of matrix synthesis, cell death, and
apoptosis of chondrocytes. In vitro experiments conﬁrmed
that mechanical shear stress increases the production of
oxidants in cartilage explants [90].
In a study, serum samples of 29 patients with knee OA
and 26 healthy controls were analyzed for their oxidative sta-
tus [92]. Total antioxidant capacity (TAC) and, in addition,
the oxidative stress index (OSI Index) were determined as
antioxidant parameters. The oxidative stress was measured
based on total peroxide (TP) content and lipid hydroperox-
ide and the OSI Index was calculated from the TP/TAC ratio.
Compared with the healthy controls, the OA patients had a
signiﬁcantly higher OSI Index, whereas all the markers for
antioxidant activity were lower. Prolidase activity (collagen
synthesis marker) was also signiﬁcantly lower in the OA
patients. Moreover, the enzyme activity correlated positively
with the antioxidant concentration (TAC) and negatively
with oxidative stress (OS). Hence, the higher the antioxidant
concentration, the better the cartilage metabolism process.
Conversely, oxidative stress was associated with impaired
cartilage metabolism [92].
A working group showed that OA patients have a sig-
niﬁcantly reduced concentration of antioxidants (vitamins
C and E) and increased oxidative stress. Oxidative stress
was measured on the basis of the malondialdehyde (MDA)
concentration [93].
Therefore, OA treatment should not only focus on
regeneration and anti-inﬂammatory processes but also on
the reduction of oxidative stress in these patients. Positive
eﬀects on OA have been found for a number of vitamins and
minerals (for review see [143, 144]).
Vitamin C, for example, stimulates collagen synthesis,
and to a lesser extent the synthesis of aggrecan. Proteoglycan
synthesis is increased in chondrocyte cultures [145]( f o r
review see [143, 146]). An animal study showed that vitamin
Ch a sap r o t e c t i v ee ﬀect on knee cartilage [147]. The eﬀect of
chondrocyte protection could be mediated by its antioxidant
capacity. Similar results were reported for vitamin E, which
is known for its strong antioxidant eﬀects, its protection
againstROS,andenhancementofchondrocytegrowth[143].
The positive eﬀects of vitamin E were demonstrated in
clinical trials. Patients treated with vitamin E displayed a
signiﬁcant reduction in pain when compared to placebo, and
comparable eﬀects to diclofenac (for review see [143]).
Selenium, zinc, and copper are minerals under discus-
sion as supporting OA treatment. They exhibit antioxidant
characteristics and are part of antioxidant enzymes. Rats
fed with a low selenium diet showed a decrease in sulfo-
transferase activity. This enzyme is involved in the process
of glycosaminoglycan synthesis, which is important for the
cartilage matrix [148]. In a double-blind, placebo-controlled
study, the combination of selenium and vitamins A, C,
and E, had a positive but nonsigniﬁcant eﬀect that tends
to improve pain and stiﬀness in OA patients, compared
to placebo [149]. Manganese is a component of glycosal
and xylosyltransferase enzyme which are responsible for
the glycosidic binding and thus for the glycosaminoglycan
synthesis. Manganese is also involved in the cross-linking
of collagen ﬁbrils and inhibits elastin-degrading elastases
[150]. Copper, an essential component of lysyl oxidase,
contributes to the cross-linking of collagen and elastin in
cartilage and bone tissue, and molybdenum is a cofactor of
sulﬁtoxidase enzyme producing sulfates which are important
for proteoglycan synthesis.
SynergisticActionofChondroprotectives,Omega-3FattyAcids,
and Other Nutrients. Omega-3 polyunsaturated fatty acids
(PUFAs), such as linolenic acid and eicosapentaenoic acid
(EPA), are found in walnut, ﬂaxseed, and ﬁsh oils. They
are known for their anti-inﬂammatory actions, which hasInternational Journal of Rheumatology 11
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Figure 3: A greater proportion of patients with combination ther-
apy GlcN·S + O-3 FA showed the highest WOMAC improvements
of 80–100% [126].
been shown in several studies (see [144, 147, 151]). They
have been successfully used in clinical trials, mainly to
treat rheumatoid arthritis [152–154]. In vitro studies showed
that omega-3 fatty acids increase collagen synthesis and
decrease the inﬂammation mediator PGE2 [155]. EPA, when
oxygenated, results in the bioactive product resolving E1
(RvE1). By activation of a speciﬁc receptor, ChemR23, RvE1
dramatically reduces inﬂammatory processes by inhibiting
the NF-κB pathway that is responsible for many of these
processes [156]. Omega-3 fatty acids decrease IL-1-induced
aggrecanase and collagenase activity and reduce mRNA
expression of ADAMTS-4, COX-2, IL-1α,a n dT N F - α.F u r -
thermore, they decrease the protein levels of several MMPs
[157]( f o rr e v i e ws e e[ 144]).
PUFAs are important components of a dietary OA ther-
apy. Oxygen radicals are eliminated through the supplemen-
tation of antioxidants. They are generated to an increased
extent in OA and are involved in cartilage degeneration
(99,152), but also promote inﬂammatory processes in the
body quite generally. Numerous studies have dealt with the
anti-inﬂammatory eﬀects of the polyunsaturated fatty acids
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
and their role in cartilage metabolism [157].
A recent study was able to demonstrate that the com-
bined administration of EPA and DHA in a glucosamine
therapy markedly alleviated the discomfort of knee and
hip joint OA patients [126]. In this randomized study, 177
patients suﬀering from moderate to severe OA of the knee
or hip joint were subdivided in two groups. One group
took a combination of 1,500mg of glucosamine sulfate plus
the omega-3 fatty acids EPA and DHA as well as vitamins
A, D, and E every day for 26 weeks. The other group was
given a preparation without EPA and DHA. At baseline and
at weeks 13 and 26 the subjects were examined and their
complaints were documented based on the Western Ontario
and McMaster Universities Osteoarthritis-Index (WOMAC).
Both groups showed an improvement as a result of the
therapy demonstrated by a reduction in the WOMAC pain
score of 20% or more. If the criterion of therapy success was
greater, for example, 80%, a signiﬁcantly greater number of
patients in the combination group (52.2%) reached this aim
as compared to the group taking the preparation without
EPA and DHA (37.9%; P = 0.044; Figure 3). In addition,
typical OA symptoms such as joint stiﬀness or joint pain had
already decreased at week 13 and towards the end of the trial
continued to decrease by 48.5% to 55.5% in the EPA and
DHA group as compared to 41.7% to 55.3% in the control
group.
The results of these in vivo and in vitro experiments
clearly demonstrate an anti-inﬂammatory action for glu-
cosamine, chondroitin sulfate, hyaluronic acid, and omega-
3 fatty acids. Due to these abilities, it is plausible that
such nutrients can reduce collagen degradation [157]i n
osteoarthritis.
5. Conclusion
Based on the preclinical and clinical data, it is obvious that
chondroprotectivessuchasglucosamine,chondroitinsulfate,
and other nutrients, such as antioxidants and PUFAs, can
modulate osteoarthritis. In long-term use they exhibit, in
contrast to NSAIDs, an excellent safety proﬁle, with as few
adverse events as placebo.
The chondroprotectives are essential components of
the cartilage metabolism and stimulate important cartilage
regeneration processes, thereby adjusting the imbalance of
catabolic and anabolic processes in osteoarthritis.
Newer data point out that inﬂammation and oxidative
stress are characteristics of all stages of the disease. Chon-
droprotectives are able to inhibit many of these processes.
They defend chondrocytes against oxidative stress-induced
apoptosis, reduce the inﬂammatory mediator-induced joint
cartilage degeneration, and reactivate the inﬂammation-
reduced anabolic processes of extracellular matrix com-
ponents. This leads to reduced inﬂammation, swelling,
and pain, and to an increased mobility of the aﬀected
joints. Especially when used in combination with other
nutrients, such as antioxidants and omega-3 fatty acids,
these substances are able to exert synergistic eﬀects on the
osteoarthritic joints.
Recently new study results were published that demon-
strate promising eﬀects of further food substances or phy-
tochemicals, such as contained in ginger extracts, showing
various antiosteoarthritic actions and, for example, even
intra-articular resveratrol showing chondroprotective eﬀects
in a rat animal model.
In summary, future “nutraceutical” approaches to OA
most likely will have to be more complex and should include
glucosamine sulfate (and/or chondroitin sulfate) together
with hyaluronic acid, collagen hydrolysate, and several other
nutrients which were shown to have promising actions on
joint cartilage, synovial ﬂuid, and overall clinical outcome in
OA patients.
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